drugset / Trial / NCT00343954

PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease

NCT00343954

Phase 1 Unknown 12 enrolled Angiogenix
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate PK and PD responses to L-citrulline given orally for four weeks to patients with sickle cell disease who are otherwise healthy.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject L-citrulline Other / unclassified 1000 mg Oral

Indications